Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSJ117 add-on therapy in adults with severe uncontrolled asthma
jRCT2080225330Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ecleralimab in asthma (6 arms), sponsored by Novartis. Started Aug 2020; status: completed.
02
Drugs
ecleralimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080225330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225330.